iXensor partners with Innova Medical Group to develop ‘smart’ ovulation test

The healthtech company iXensor has announced a partnership with Innova Medical Group to develop a ‘smart’ ovulation test.

Innova Medical Group, a global platform for screening and diagnosis that delivers rapid test kits to customers, is currently developing on a new ovulation test with a fully integrated hardware, app and cloud solution.

The pandemic has meant that some medical testing shifted from central labs to point-of-care and now to consumers’ homes as self-testing.

iXensor’s first product, PixoTech, could play a significant role in addressing the growing demands of smart at-home testing by working with lateral flow assay manufacturers, pharmaceutical partners, and medtech innovators, the company says.

Based on the PixoTech technology and PixoTech XLab, the virtual co-development laboratory, the company has developed both at-home self-test and point-of-care testing products across women’s health, diabetes, infectious and cardiovascular diseases certified by the US FDA and CE-Mark.

“We are impressed by iXensor’s technology that turns smartphones into self-testing devices and empowers users at their point of need,” said Xavier Guerin, President of Europe at Innova Medical Group.

“We are delighted to partner with iXensor for the development of our PHRONESIA Smart Ovulation Test with a fully integrated hardware, app and cloud solution, all being manufactured in a cost-effective manner.”

Technology-assisted decentralised testing and management are seen as one of the critical areas in which quality of care can be improved while reducing costs.

Dr Carson Chen, CEO of iXensor, said: “At iXensor, we are excited to work seamlessly with our global partners to empower tomorrow’s smart healthcare through our integrated interdisciplinary expertise in medical engineering, biochemistry, and information technology.

“At the same time, our partners can fully leverage Taiwan’s unique position as the Silicon Island with its strong ICT innovation and supply chain.”

In 2017, the Taiwanese company introduced the PixoTest Blood Glucose Monitoring System as the world’s first US FDA-approved smartphone camera-based blood test.

Currently it is active in technology licensing, partner co-developments, and contract development and manufacturing services for decentralised testing.